Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Bcr-abl/abl ratio and FISH positivity - relation to c-kit expression and dual esterase activity in CML patients on Gleevec therapy (CROSBI ID 518444)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Radić Antolic, Margareta ; Sučić, Mirna ; Zadro, Renata ; Davidović-Mrsić, Sanja ; Marković-Glamočak, Mirjana ; Ries, Sunčica ; Gjadrov-Kuvezdić, Koraljka ; Vrbanus, Ljiljana ; Batinić, Drago ; Dubravčić, Klara et al. Bcr-abl/abl ratio and FISH positivity - relation to c-kit expression and dual esterase activity in CML patients on Gleevec therapy // Haematologica. 2006. str. 481-481

Podaci o odgovornosti

Radić Antolic, Margareta ; Sučić, Mirna ; Zadro, Renata ; Davidović-Mrsić, Sanja ; Marković-Glamočak, Mirjana ; Ries, Sunčica ; Gjadrov-Kuvezdić, Koraljka ; Vrbanus, Ljiljana ; Batinić, Drago ; Dubravčić, Klara ; Juričević, Mirjana ; Labar, Boris

engleski

Bcr-abl/abl ratio and FISH positivity - relation to c-kit expression and dual esterase activity in CML patients on Gleevec therapy

Background: Chronic myelogenous leukemia (CML) is a myeloproliferative disease with t(9 ; 22) and/or BCR/ABL fusion gene. One of treatment options for CML patients is inhibition of BCR/ABL and c-kit (CD117) tyrosine kinase activity with imatinib mesylate (Gleevec). Aim of the study: To analyze CD117 expression and dual esterase activity in bone marrow hematopoietic cells (HCs) of CML patients on Gleevec therapy and to correlate the results with percentage of FISH Ph positive HCs and bcr-abl/abl ratio. Methods: 22 bone marrow specimens of 17 CML patients on Gleveec therapy (duration of therapy 4 – 32 months) were analyzed by FISH and quantitative RT-PCR, immunocytochemical APAAP CD117 expression and cytochemical dual esterase activity. Patients were divided in subgroups according to duration of therapy (less than 6, 6-12 and more than 12 months). Results: Patients with leukocyte differential count changes had high bcr-abl/abl ratio, FISH Ph and CD117 positive HCs. Medians of CD117 and FISH Ph positive HCs were highest in CML patients during the first 6 months of Gleveec treatment, but correlation of these two parameters was low (0.19). There was no statistical difference when medians of CD117 and dual esterase positive HCs were compared between subgroups. Correlation of FISH Ph positive HCs and bcr-abl/abl ratio was high (0.68) with constant decrease in percentage of FISH Ph positive HCs and bcr-abl/abl ratio during follow-up. Conclusions: According to low correlation obtained between CD117 expression and dual esterase activity with percentage of FISH Ph positive HCs and bcr-abl/abl ratio, FISH and quantitative RT-PCR are the methods of choice for monitoring the efficiency of Gleevec therapy.

bcr-abl/abl ratio; CD117 expression; Gleevec

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

481-481.

2006.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Haematologica

0390-6078

Podaci o skupu

Congress of the European Hematology Association (11 ; 2006)

poster

15.06.2006-18.06.2006

Amsterdam, Nizozemska

Povezanost rada

Temeljne medicinske znanosti

Indeksiranost